Panama, Pharma, and the AI Race: How Beijing Plays the Long Game Under Pressure
When Panamanian officials addressed the United Nations on 26 May 2026, they chose their words with the precision of a government acutely aware of where its livelihoods lie. According to the South China Morning Post, Panama called for dialogue and bridge-building at the world body, without naming either Washington or Beijing directly, even as the two powers jostle over influence at the canal that generates roughly 40 percent of Panama's state revenue. The canal is neutral under the 1977 Torrijos-Carter Treaties, which transferred it to Panamanian control in 1999, and Panama has no appetite to renegotiate that legal architecture. What it wants is space to manage its own relationships — with the United States, which accounts for roughly 75 percent of canal transits, and with China, which has become a significant investor in Panamanian port and logistics infrastructure. The US has made clear it views Chinese presence near the canal as a strategic concern; Chinese state media has characterised American pressure on Panama as interference in a sovereign state's economic decisions. Panama's posture — articulate its own principles, keep both capitals engaged, let the treaties hold — is the posture of a middle-income country that has calculated it cannot afford to choose, and is trying to make that calculation permanent.
The canal question is one front in a contest that, on the evidence of three separate developments in late May 2026, has no single decisive battleground. On the same day Panamanian diplomats were speaking in New York, Reuters reported that the head of the China Association for Medical Devices — the industry body representing the sector the government has designated as strategically significant — stated that Beijing's scrutiny of sensitive tech transactions had not affected the pharmaceutical or medical equipment industry. The statement is a reassurance from an official voice, and its existence itself is informative: the government has been reviewing outbound investment in sensitive technology sectors, a review that has prompted anxiety among Chinese firms about regulatory unpredictability. The JW chief's assertion that pharma has not been caught in that net is data about where the government drawing lines. It is not data about whether the broader environment for Chinese industry has become more volatile — only that the specific sector most directly tied to domestic health security and export revenue has, at least so far, been treated as a separate category.
Betting markets are not polls, and Polymarket's market assigning a 19 percent probability to a Chinese company achieving best-in-class AI model status by year-end is best read as a summary of where the speculative community thinks the race stands right now, not a prediction. The number is revealing precisely because it is not 50-50. The market is saying that, at present, the consensus expectation is that American firms maintain a lead. The market is not saying that lead is insurmountable — a 19 percent chance of a dramatic upset is non-trivial in a domain where breakthroughs can arrive nonlinearly. The question the market is pricing is not just technical capability but the conditions that make technical capability achievable: chip availability, talent retention, the willingness of foreign partners to continue providing compute infrastructure, and the resilience of Chinese AI labs to operate under the kind of sustained regulatory and trade pressure that Washington has been building since 2022.
The United States has, over the past four years, layered multiple tools on top of each other. Investment restrictions targeting Chinese AI companies. Expanded export controls on advanced semiconductors, most recently applied to entities including China's largest chipmaker, SMIC. Diplomatic pressure on allies to exclude Huawei from 5G networks. Proposed legislation requiring review of American outbound investment in Chinese AI and semiconductor firms. Each measure has a stated rationale — preventing military applications, protecting supply chain integrity, preserving American technological primacy — and each creates real friction for Chinese companies attempting to maintain development trajectories. The friction is not hypothetical; it shows up in capital allocation decisions, in the cost of compute, in the choices of overseas partners weighing their own exposure to secondary sanctions risk.
Beijing's responses to this pressure are consistent and can be grouped into three categories. The first is structural: the government has made technological self-sufficiency a formally articulated policy objective, backed by state-directed credit, research funding, and regulatory preferences for domestic suppliers. The pharmaceutical sector — where the JW chief's statement was made — is explicitly part of that push, with the Made in China 2025 initiative and its successors naming biotech as a pillar. The second is diplomatic: Chinese officials and state media have characterised American restrictions as protectionism, unilateralism, and interference in normal commercial relations — framing that is designed for audiences outside the G7 as much as for domestic consumption. The third is adaptive: Chinese firms have shown a capacity to improvise around constraints, developing alternative supply chains, accelerating domestic chip development, and maintaining commercial relationships in markets where governments are not aligned with Washington's technology posture. None of these responses guarantees that the restrictions will fail. They do suggest that the restrictions are being absorbed rather than accepted, and that Beijing's strategic calculation — that technological capacity is existential to regime legitimacy and national security — means it will pay whatever price is necessary to close gaps.
For Washington, the problem is not that these measures are ineffective. Export controls on advanced chips have meaningfully raised the cost and reduced the availability of cutting-edge compute for Chinese labs. Investment restrictions have deterred some capital flows that would otherwise have accelerated Chinese capability. The problem is that the strategic objective — to permanently cap Chinese AI development below the level necessary to challenge American primacy — may be unachievable without costs that Washington is not currently prepared to absorb. Cutting off China's access to the global semiconductor supply chain requires either compelling allies with significant manufacturing capacity to enforce similar controls, or accepting the costs of a bifurcated technology ecosystem in which American firms are partially excluded from the world's largest manufacturing base. Neither option is costless.
The structural frame that best explains the current moment is not a simple story of decline or of resilience. It is a story of friction — the accumulation of pressures that, individually, China can absorb, reroute, or offset, but that collectively alter the environment in which its development model operates. The canal dispute is a proxy for a deeper question: who sets the terms of access to the infrastructure on which global trade depends, and what leverage does each side have to shape those terms. Pharmaceutical manufacturing is a proxy for another question: can a state that has made technological self-sufficiency a political imperative sustain the investment and talent development necessary to achieve it under conditions of external restriction. The AI race is a proxy for the same underlying contest, with higher stakes because AI is not yet a mature technology — the outcome is not determined, and the trajectory depends on decisions not yet made.
The historical precedents are instructive but not dispositive. Japan in the 1980s faced comparable pressure when its semiconductor and automotive industries appeared poised to dominate global markets. The Plaza Accord, voluntary export restraints, and bilateral negotiations produced measurable slowdowns in Japanese market share. But Japan's GDP per capita remained broadly comparable to Western levels, and its economic integration with the United States deepened rather than reversed. China is a larger, more self-contained economy than Japan was, with a different political system and a different set of incentives to sustain strategic investment over decades rather than electoral cycles. The analogy works up to a point; beyond that point, the differences matter more than the similarities.
The stakes are not only geopolitical. If the United States succeeds in permanently restricting Chinese access to advanced AI and semiconductor technology, the costs will be distributed across the global economy — in higher prices for electronics, in reduced competitiveness for firms that depend on integrated global supply chains, in the fragmentation of the internet into spheres with different technical standards and governance norms. If China succeeds in building independent capability, the balance of economic and military power shifts in ways that alter the options available to every country that currently relies on American security guarantees. Neither outcome is foreordained. The current moment is one in which decisions being made — in Beijing, in Washington, in capitals across the Global South that are watching to see which model of engagement proves more durable — will shape which direction the trajectory runs.
What remains uncertain, and what the available sources do not fully resolve, is whether the friction being imposed on China's development model is sufficient to alter Beijing's strategic calculus, or whether it is the kind of pressure that produces adaptation rather than retreat. The Polymarket odds suggest that, at least in the near term, the speculative community does not expect a dramatic Chinese breakthrough in AI. That assessment may be right. It may also reflect the difficulty of pricing a technology whose development depends on decisions that have not yet been made and whose outcomes are inherently hard to predict. The sources do not indicate the terms of any new US-Panama security agreement reportedly under negotiation. The Reuters reporting on pharma does not specify which sensitive tech sectors are under active review beyond that sector. And the Polymarket market is a snapshot of sentiment at a single point in time, not a forecast.
This publication has tried, in this piece, to treat the three developments as connected data points in a single structural contest rather than as isolated news items. The dominant wire framing on each — canal tensions as a bilateral US-Panama story, pharma scrutiny as a domestic Chinese regulatory question, the AI race as a straightforward American lead — is accurate as far as it goes. What it misses is the way each piece is legible as a test of whether Washington's pressure campaign is degrading Chinese capacity to project economic and technological influence, or whether Beijing's adaptive machinery is operating as intended. The evidence, on present showing, suggests the contest is more durable than either side's strongest advocates would prefer to admit.
This article drew on reporting by the South China Morning Post, Reuters, and Polymarket, with background on the Panama Canal's geopolitical significance derived from publicly available sources.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- http://reut.rs/4f9MKGr